<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo270046" xml:lang="en" article-type="case-study"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39712905</article-id><article-id pub-id-type="pmc">PMC11662994</article-id>
<article-id pub-id-type="doi">10.1002/deo2.70046</article-id><article-id pub-id-type="publisher-id">DEO270046</article-id><article-categories><subj-group subj-group-type="overline"><subject>Case Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Profound gastric mucosal changes and severe rebound acid hypersecretion after long&#x02010;term Vonoprazan use: A case report</article-title><alt-title alt-title-type="left-running-head">SUDA <sc>et&#x000a0;al</sc>.</alt-title></title-group><contrib-group><contrib id="deo270046-cr-0001" contrib-type="author" corresp="yes"><name><surname>Suda</surname><given-names>Hiroko</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-4060-7097</contrib-id><xref rid="deo270046-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>sudahiro0825@gmail.com</email></address></contrib><contrib id="deo270046-cr-0002" contrib-type="author"><name><surname>Eto</surname><given-names>Sachi</given-names></name><xref rid="deo270046-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270046-cr-0003" contrib-type="author"><name><surname>Sakurai</surname><given-names>Koichi</given-names></name><xref rid="deo270046-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="deo270046-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Hattori Clinic</institution>
<city>Kumamoto</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Hiroko Suda, Hattori Clinic, 2&#x02010;12&#x02010;35 Shin&#x02010;machi, Chuo&#x02010;ku, Kumamoto City, Kumamoto 860&#x02010;0004, Japan.<break/> Email: <email>sudahiro0825@gmail.com</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="49">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e70046</elocation-id><history>
<date date-type="rev-recd"><day>03</day><month>12</month><year>2024</year></date>
<date date-type="received"><day>21</day><month>10</month><year>2024</year></date>
<date date-type="accepted"><day>09</day><month>12</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e70046.pdf"/><abstract><title>Abstract</title><p>Vonoprazan is a novel acid blocker with greater potency than proton pump inhibitors. A Japanese study reported no significant safety concerns over 5 years of Vonoprazan use; however, elevated serum gastrin and increased parietal cell and foveolar hyperplasia were observed, and long&#x02010;term safety data beyond 5 years are limited. We report a case that used Vonoprazan for 6 years, complicated by significant gastric epithelial changes during treatment and acute duodenal mucosal lesions&#x000a0;following its discontinuation. A 76&#x02010;year&#x02010;old, treated with proton pump inhibitors for over 10 years, was switched to Vonoprazan due to his worsening symptoms. After its use, hemorrhagic hyperplastic polyps became prominent. Given concerns about Vonoprazan's effect on the gastric epithelium, the medication was changed to high&#x02010;dose H2 blocker therapy. Two months later, the patient complained of vomiting and black tarry stools. Esophagogastroduodenoscopy revealed a significant reduction of gastric polyps but multiple erosions and ulcers in the duodenum. This case indicates the potent effects of Vonoprazan on the gastric mucosa and the risk of severe rebound acid hypersecretion after its long&#x02010;term use.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo270046-kwd-0001">gastric mucosa</kwd><kwd id="deo270046-kwd-0002">gastroesophageal reflux</kwd><kwd id="deo270046-kwd-0003">proton pump inhibitors</kwd><kwd id="deo270046-kwd-0004">rebound acid hypersecretion</kwd><kwd id="deo270046-kwd-0005">Vonoprazan</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="0"/><page-count count="4"/><word-count count="2028"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo270046-sec-0010"><label>1</label><title>INTRODUCTION</title><p>Vonoprazan, a potassium&#x02010;competitive acid blocker, inhibits H<sup>+</sup>/K<sup>+</sup> ATPase with greater potency than proton pump inhibitors (PPIs). It offers several advantages over PPIs, including stability in acidic conditions, unaffected by food intake, quicker onset of acid suppression, and resistance to CYP2C19 polymorphism. A Japanese randomized controlled trial evaluating the safety of Vonoprazan over 5 years for gastroesophageal reflux disease (GERD) maintenance therapy, reported no increased risk of neoplastic changes and enterochromaffin&#x02010;like (ECL) hyperplasia, although elevated serum gastrin, and higher incidence of parietal cell and foveolar hyperplasia were noted compared to PPI.<xref rid="deo270046-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>
</p><p>Endoscopic findings associated with long&#x02010;term PPI use, such as fundic gland polyps, hyperplastic polyps, multiple white and flat elevated lesions, cracked and cobblestone&#x02010;like mucosa, and black spots, are well&#x02010;known. Vonoprazan use has been reported to show additional unique features, including gastric mucosal redness, white spots, and web&#x02010;like mucus.<xref rid="deo270046-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>Given the stronger acid inhibition and higher hypergastrinemia driven by Vonoprazan, its long&#x02010;term safety remains a concern. In this report, we present a case of a 76&#x02010;year&#x02010;old man who used Vonoprazan for 6 years, complicated by significant gastric epithelial changes, and acute duodenal mucosal lesions&#x000a0;(ADML) that developed after switching from Vonoprazan to histamine type 2 receptor antagonist (H2&#x02010;blocker).</p></sec><sec id="deo270046-sec-0020"><label>2</label><title>CASE REPORT</title><p>A 76&#x02010;year&#x02010;old man with a history of hypertension and post&#x02010;operation of thoracoabdominal aortic aneurysm had been receiving anti&#x02010;acid medication for heartburn for over 10 years. He has been prescribed antihypertensive and antilipidemic medications, without the use of anticoagulants or non&#x02010;steroidal anti&#x02010;inflammatory drugs. His liver and renal function were within normal limits. His <italic toggle="yes">Helicobacter pylori</italic> status was determined to be negative based on a negative serum anti&#x02010;<italic toggle="yes">H. pylori</italic> antibody test (&#x0003c;&#x000a0;3 U/mL) and a lack of mucosal atrophy on endoscopic examination. Initially treated with Omeprazole 20 mg, his medication was switched to Esomeprazole 20 mg 7 years ago due to worsening symptoms. Despite this change, Esomeprazole failed to adequately control his reflux symptom, even though endoscopic evaluation revealed grade N. Consequently, treatment with Vonoprazan 20 mg was initiated 6 years ago. His symptoms resolved soon after starting Vonoprazan; however, red hyperplastic polyps became prominent in addition to previously observed fundic gland polyps (Figure&#x000a0;<xref rid="deo270046-fig-0001" ref-type="fig">1</xref>). After 59 months on Vonoprazan, a polypectomy was performed to remove hemorrhagic hyperplastic polyps. Despite the intervention, other hyperplastic polyps continued to grow (Figure&#x000a0;<xref rid="deo270046-fig-0002" ref-type="fig">2</xref>). Suspecting a potential influence of Vonoprazan, the medication was switched to H2 blocker 20 mg twice daily, following a two&#x02010;week temporary transition period with Esomeprazole 20 mg (<xref rid="deo270046-supinfo-0001" ref-type="">Supporting Information Figure</xref>).</p><fig position="float" fig-type="FIGURE" id="deo270046-fig-0001"><label>FIGURE 1</label><caption><p>(a&#x02013;d) Endoscopic images (a, b) before the initiation of Vonoprazan therapy. (c, d) after 19 months of Vonoprazan use, linear and spotty redness and multiple small hyperplastic polyps in the body became prominent in addition to previously observed fundic gland polyps.</p></caption><graphic xlink:href="DEO2-5-e70046-g001" position="anchor" id="jats-graphic-1"/></fig><fig position="float" fig-type="FIGURE" id="deo270046-fig-0002"><label>FIGURE 2</label><caption><p>(a&#x02013;d) Endoscopic images (a, b) after 59 months of Vonoprazan use, showing a hemorrhagic polyp (blue arrow) before resection. (c, d) After 69 months of Vonoprazan use, revealing the growth of new polyps was growing following the resection (yellow circle).</p></caption><graphic xlink:href="DEO2-5-e70046-g002" position="anchor" id="jats-graphic-3"/></fig><p>One month later, the patient complained of mild heartburn and diarrhea. At the 2&#x02010;month follow&#x02010;up, his symptoms had worsened, with vomiting, black tarry stools, and a 7 kg weight loss. Physical examination revealed a slightly distended abdomen with tenderness from the epigastric region to the lower abdomen. Laboratory tests showed progressive anemia and elevated blood urea nitrogen levels, suggesting possible upper gastrointestinal bleeding (Supporting Information Table).</p><p>Esophagogastroduodenoscopy revealed a significant reduction in the size and number of gastric polyps. However, multiple erosions, including 10 mm ulcers, were observed from the superior duodenal angle to the descending part of the duodenum (Figure&#x000a0;<xref rid="deo270046-fig-0003" ref-type="fig">3</xref>). Additionally, the patient's reflux esophagitis, which had been grade N during Vonoprazan therapy, had worsened to grade B.</p><fig position="float" fig-type="FIGURE" id="deo270046-fig-0003"><label>FIGURE 3</label><caption><p>(a&#x02013;c) Endoscopic images after switching to H2 blockers, showing a significant deduction of polyps in the stomach. (d) Endoscopic images revealing ulcers in the duodenum. This image shows an ulcer located in the superior duodenal angle.</p></caption><graphic xlink:href="DEO2-5-e70046-g003" position="anchor" id="jats-graphic-5"/></fig><p>H2 blocker was switched back to Vonoprazan to manage the duodenal ulcers, leading to a rapid solution of symptoms. Subsequent endoscopy performed 1 month after restarting Vonoprazan confirmed improvement of ADML. Histological analysis of gastric tissue showed parietal cell hyperplasia in the corpus of the upper greater curvature and G&#x02010;cell hyperplasia in the antrum of the upper greater curvature (Figure&#x000a0;<xref rid="deo270046-fig-0004" ref-type="fig">4</xref>). Following this confirmation, the patient's medication was changed to esomeprazole 20 mg daily. After approximately 3 months, there were no notable changes in symptoms or endoscopic findings.</p><fig position="float" fig-type="FIGURE" id="deo270046-fig-0004"><label>FIGURE 4</label><caption><p>(a&#x02013;c) Histological images. (a) Hematoxylin and eosin staining showing parietal cell hyperplasia in the gastric body, (b) Anti&#x02010;synaptophysin staining showing increased enterochromaffin&#x02010;like&#x000a0;cells in the gastric body, and (c) Anti&#x02010;gastrin staining showing G cell hyperplasia in the antrum. Scale bars; 250 &#x000b5;m.</p></caption><graphic xlink:href="DEO2-5-e70046-g004" position="anchor" id="jats-graphic-7"/></fig><p>During the clinical course, the patient's serum gastrin levels were measured as 481 pmol/L while on Vonoprazan, 100 pmol/L on Esomeprazole, and 80.6 pmol/L on an H2 blocker.</p></sec><sec id="deo270046-sec-0030"><label>3</label><title>DISCUSSION</title><p>This case highlights significant gastric mucosal changes in a patient with 6 years of Vonoprazan use, coinciding with the severe hyperacid disorder during the de&#x02010;prescribing process of Vonoprazan. It offers insight into the potential complications of long&#x02010;term Vonoprazan therapy and its withdrawal.</p><p>Vonoprazan appears to have a more intense effect on the gastric mucosa compared to PPIs. In this case, the development of reddish hyperplastic polyps after switching from PPI to Vonoprazan, and their prompt regression within 2 months during transitioning to H2&#x02010;blocker, indicates that Vonoprazan has a more pronounced effect on the gastric mucosa than other acid&#x02010;suppressing drugs. While a few case reports have described a reduction in the number and size of gastric polyps about one year after discontinuation of Vonoprazan,<xref rid="deo270046-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> the strikingly rapid mucosal changes observed in this case are notable. Furthermore, the positive correlation between elevated serum gastrin levels and the growth of hyperplastic polyps in this patient is consistent with a previous report showing that higher gastrin levels increased the risk of hyperplastic polyps in PPI users.<xref rid="deo270046-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><p>This case demonstrates the risk of rebound acid hypersecretion (RAHS) after discontinuing long&#x02010;term Vonoprazan use. Despite high&#x02010;dose H2 blocker replacement therapy, the patient developed ADML. The acid&#x02010;inhibitory effect of the H2 blocker was insufficient to suppress his acid secretion. RAHS is characterized by acid hypersecretion status following the withdrawal of long&#x02010;term acid&#x02010;suppressive therapy, driven by the trophic effects of hypergastrinemia on ECL and parietal cells. Studies in mice have shown a relatively long lifetime of these cells; the lifetime of parietal cells exceeds 300 days,<xref rid="deo270046-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> while ECL cells have a cell cycle time of approximately 60 days.<xref rid="deo270046-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Therefore, acid hypersecretion can persist until these cell populations gradually return to baseline levels, even after rapid normalization of elevated serum gastrin levels following discontinuation of acid&#x02010;suppressing drugs. Fossmark et&#x000a0;al. showed that RAHS can last from 8 to 26 weeks after stopping PPI medication.<xref rid="deo270046-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> In this case, the patient's prolonged use of Vonoprazan likely exacerbated the severity of RAHS. His histological findings, which demonstrated prominent parietal and G cell hyperplasia are compatible with this theory, though ECL cell hyperplasia was less pronounced in comparison. Another possible reason for the severity of his RAHS is his <italic toggle="yes">H. pylori</italic>&#x02010;negative status. Gillen et&#x000a0;al. showed that RAHS occurred in <italic toggle="yes">H. pylori</italic>&#x02010;negative subjects after PPI treatment, while RAHS was partially masked in <italic toggle="yes">H. pylori</italic>&#x02010;positive subjects.<xref rid="deo270046-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Since <italic toggle="yes">H. pylori</italic> inhibits acid production through multiple mechanisms&#x02014;such as direct damage to the gastric epithelial cells, stimulation of proinflammatory cytokines, suppression of H<sup>+</sup>/K<sup>+</sup>&#x02010;ATPase&#x003b1;subunit transcription, and enhancement of somatostatin release, it is plausible that acid rebound is more prominent in <italic toggle="yes">H. pylori</italic>&#x02010;negative patients.</p><p>Tanaka et&#x000a0;al. reported that the discontinuation of Vonoprazan/PPI resulted in reflux symptoms in 28.3% of cases, with the severity and frequency of symptoms being higher in the Vonoprazan group compared to the PPI group, although the difference was not statistically significant.<xref rid="deo270046-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Our case supports these findings and is particularly noteworthy, as it demonstrates rapid gastric epithelial changes and the occurrence of a more severe complication, in addition to reflux symptoms.</p><p>Although the effect of long&#x02010;term PPI use before Vonoprazan cannot be overlooked, the potent effect of Vonoprazan likely exacerbated the acid hypersecretion in the gastric epithelium. While numerous studies have examined RAHS, the underlying risk factors remain incompletely understood.<xref rid="deo270046-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Based on the physiological mechanisms of RAHS, which is driven by hypergastrinemia induced by anti&#x02010;acid drug use, unnecessary high&#x02010;intensity or extended&#x02010;duration therapy should be avoided. Additionally, distinguishing between recurrence that warrants reinitiation of acid&#x02010;suppressive therapy and transient hyperacidity following withdrawal of these drugs can be challenging. Physicians should remain vigilant about the potential for RAHS, educate patients about this risk, and emphasize the importance of careful monitoring during and after deprescribing anti&#x02010;acid medications. For patients with a history of long&#x02010;term anti&#x02010;acid drug use, particular caution is necessary to safely taper or discontinue therapy, given the potential for severe complications like this case.</p></sec><sec sec-type="COI-statement" id="deo270046-sec-0040"><title>CONFLICT OF INTEREST STATEMENT</title><p>None</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="deo270046-supinfo-0001" position="float" content-type="local-data"/><supplementary-material id="deo270046-supitem-0001" position="float" content-type="local-data"><caption><p>Laboratory data: 69month after utilizing Vonoprazan</p></caption><media xlink:href="DEO2-5-e70046-s001.docx"/></supplementary-material></sec></body><back><ref-list id="deo270046-bibl-0001"><title>REFERENCES</title><ref id="deo270046-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo270046-cit-0001">
<string-name>
<surname>Uemura</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kinoshita</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Haruma</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Vonoprazan as a long&#x02010;term maintenance treatment for erosive esophagitis: VISION, a 5&#x02010;year, randomized, open&#x02010;label study</article-title>. <source>Clin Gastroenterol Hepatol</source>
<year>2024</year>: DOI: <pub-id pub-id-type="doi">10.1016/j.cgh.2024.08.004</pub-id> S1542&#x02010;3565(24)00770&#x02010;5.</mixed-citation></ref><ref id="deo270046-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo270046-cit-0002">
<string-name>
<surname>Kubo</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kimura</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>M</given-names>
</string-name>. <article-title>Potassium&#x02010;competitive acid blocker&#x02010;associated gastric mucosal lesions</article-title>. <source>Clin Endosc</source>
<year>2024</year>; <volume>57</volume>: <fpage>417</fpage>&#x02013;<lpage>423</lpage>.<pub-id pub-id-type="pmid">38419167</pub-id>
</mixed-citation></ref><ref id="deo270046-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo270046-cit-0003">
<string-name>
<surname>Ochiai</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ito</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kikuchi</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hoteya</surname>
<given-names>S</given-names>
</string-name>. <article-title>Long&#x02010;term endoscopic change of gastric polyp associated with administration of vonoprazan</article-title>. <source>Clin J Gastroenterol</source>
<year>2024</year>; <volume>17</volume>: <fpage>598</fpage>&#x02013;<lpage>601</lpage>.<pub-id pub-id-type="pmid">38575803</pub-id>
</mixed-citation></ref><ref id="deo270046-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo270046-cit-0004">
<string-name>
<surname>Hongo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fujimoto</surname>
<given-names>K</given-names>
</string-name>. <article-title>Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long&#x02010;term proton pump inhibitor therapy: A prospective study in Japan</article-title>. <source>J Gastroenterol</source>
<year>2010</year>; <volume>45</volume>: <fpage>618</fpage>&#x02013;<lpage>624</lpage>.<pub-id pub-id-type="pmid">20177714</pub-id>
</mixed-citation></ref><ref id="deo270046-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo270046-cit-0005">
<string-name>
<surname>Magami</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Azuma</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Inokuchi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Moriyasu</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Kawai</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hattori</surname>
<given-names>T</given-names>
</string-name>. <article-title>Cell kinetics of slow renewing cell populations in mice stomach</article-title>. <source>J Gastroenterol Hepatol</source>
<year>2002</year>; <volume>17</volume>: <fpage>262</fpage>&#x02013;<lpage>269</lpage>.<pub-id pub-id-type="pmid">11982695</pub-id>
</mixed-citation></ref><ref id="deo270046-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo270046-cit-0006">
<string-name>
<surname>Tielemans</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Willems</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Sundler</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Hakanson</surname>
<given-names>R</given-names>
</string-name>. <article-title>Self&#x02010;replication of enterochromaffin&#x02010;like cells in the mouse stomach</article-title>. <source>Digestion</source>
<year>1990</year>; <volume>45</volume>: <fpage>138</fpage>&#x02013;<lpage>146</lpage>.<pub-id pub-id-type="pmid">2197141</pub-id>
</mixed-citation></ref><ref id="deo270046-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo270046-cit-0007">
<string-name>
<surname>Fossmark</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Johnsen</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Johanessen</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Waldum</surname>
<given-names>HL</given-names>
</string-name>. <article-title>Rebound acid hypersecretion after long&#x02010;term inhibition of gastric acid secretion</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2005</year>; <volume>21</volume>: <fpage>149</fpage>&#x02013;<lpage>154</lpage>.<pub-id pub-id-type="pmid">15679764</pub-id>
</mixed-citation></ref><ref id="deo270046-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="deo270046-cit-0008">
<string-name>
<surname>Gillen</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wirz</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Ardill</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>McColl</surname>
<given-names>KE</given-names>
</string-name>. <article-title>Rebound hypersecretion after omeprazole and its relation to on&#x02010;treatment acid suppression and <italic toggle="yes">Helicobacter pylori</italic> status</article-title>. <source>Gastroenterology</source>
<year>1999</year>; <volume>116</volume>: <fpage>239</fpage>&#x02013;<lpage>247</lpage>.<pub-id pub-id-type="pmid">9922302</pub-id>
</mixed-citation></ref><ref id="deo270046-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="deo270046-cit-0009">
<string-name>
<surname>Tanaka</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Takeuchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nishida</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Examination on factors affecting symptom change after drug withdrawal in patients with mild erosive gastroesophageal reflux disease undergoing symptom&#x02010;controlled maintenance therapy with acid&#x02010;secretion inhibition drugs</article-title>. <source>Digestion</source>
<year>2023</year>; <volume>104</volume>: <fpage>270</fpage>&#x02013;<lpage>282</lpage>.<pub-id pub-id-type="pmid">36649678</pub-id>
</mixed-citation></ref><ref id="deo270046-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="deo270046-cit-0010">
<string-name>
<surname>Namikawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Bjornsson</surname>
<given-names>ES</given-names>
</string-name>. <article-title>Rebound acid hypersecretion after withdrawal of long&#x02010;term proton pump inhibitor (PPI) treatment&#x02013;Are PPIs addictive?</article-title>
<source>Int J Mol Sci</source>
<year>2024</year>; <volume>25</volume>: <fpage>5459</fpage>.<pub-id pub-id-type="pmid">38791497</pub-id>
</mixed-citation></ref></ref-list></back></article>